NOVEL PHARMACEUTICAL COMPOSITION FOR TREATING NOCICEPTIVE PAIN
    1.
    发明申请
    NOVEL PHARMACEUTICAL COMPOSITION FOR TREATING NOCICEPTIVE PAIN 审中-公开
    用于治疗疼痛的新型药物组合物

    公开(公告)号:US20110152268A1

    公开(公告)日:2011-06-23

    申请号:US13061219

    申请日:2009-09-10

    CPC分类号: C07D265/30 A61K31/5375

    摘要: The present invention relates to a pharmaceutical composition for treating nociceptive pain, containing a morpholine derivative or a pharmaceutically acceptable salt thereof, as an active ingredient. The present invention is useful in providing an excellent pharmaceutical composition for treating nociceptive pain. In addition, the present invention is particularly useful in providing a pharmaceutical composition for treating pain accompanying a disease selected from the group consisting of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, spondylosis deformans, gouty arthritis, juvenile arthritis, scapulohumeral periarthritis, and cervical syndrome, lumbago, lumbago accompanying spondylosis deformans, menalgia, pain and tumentia after inflammation, operation or injury, pain after odontectomy, and cancer pain. In addition, the present invention is particularly useful for alleviating pain in a damaged cartilage region, and is particularly useful for osteoarthritis in which NSAIDs are not effective.

    摘要翻译: 本发明涉及用于治疗伤害性疼痛的药物组合物,其含有吗啉衍生物或其药学上可接受的盐作为活性成分。 本发明可用于提供用于治疗伤害性疼痛的优异药物组合物。 此外,本发明特别可用于提供用于治疗伴随选自以下的疾病的药物组合物:选自类风湿性关节炎,类风湿性脊椎炎,骨关节炎,变形性椎关节强硬症,痛风性关节炎,幼年型关节炎,肩周炎性关节炎和子宫颈综合征, 腰痛,腰痛伴椎关节僵硬,麻痹症,炎症,手术或损伤后疼痛,咽后切除术后的疼痛,以及癌症疼痛。 此外,本发明特别可用于缓解软骨损伤区域的疼痛,特别适用于NSAIDs无效的骨关节炎。

    Vascular-permeability suppressants
    3.
    发明授权
    Vascular-permeability suppressants 失效
    血管通透性抑制剂

    公开(公告)号:US06180626B2

    公开(公告)日:2001-01-30

    申请号:US09051086

    申请日:1998-04-13

    IPC分类号: A61K31535

    CPC分类号: C07D303/22 A61K31/336

    摘要: A vascular permeability suppressant includes an oxaspirooctane derivative of the general formula (I): [wherein, R1 represents, for example, lower alkylcarbamoyl group or protected carbamoyl group, R2 represents lower alkoxyl group, and R3 represents the formula: or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. Particularly, for example, an agent that can prevent retention of carcinomatous pleural effusion or carcinomatous ascites.

    摘要翻译: 血管渗透性抑制剂包括通式(I)的氧杂辛烷衍生物:[其中,R 1表示例如低级烷基氨基甲酰基或被保护的氨基甲酰基,R 2表示低级烷氧基,R 3表示下式:或其药学上可接受的盐 与药学上可接受的载体一起。 特别是,例如可以防止癌性胸腔积液或癌性腹水保留的药剂。